决定异体 CAR T 细胞排斥与扩增的细胞和分子机制
Cellular and molecular mechanisms determining allogeneic CAR T cell rejection and expansion.
英文原题:Base-edited CAR T cells for combinational therapy against T cell malignancies.
Base-edited CAR T cells for combinational therapy against T cell malignancies.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
采用嵌合抗原受体(CAR)T 细胞靶向 T 细胞恶性肿瘤时,共享 CD3、CD7 等抗原会导致“T 细胞杀 T 细胞”的相互杀伤。碱基编辑可通过引入终止密码子或去除剪接位点,实现对问题抗原基因表达的精准破坏。
我们描述了一种制备抗相互杀伤 T 细胞的方法:在通过慢病毒表达 CD3 或 CD7 特异性 CAR 前,依次去除 TCR/CD3 和 CD7。对碱基编辑细胞的分子分析证实,与传统 Cas9 处理细胞中检测到的染色体易位已被消除。有趣的是,3CAR/7CAR 共培养产生“自我富集”效应,形成 99.6% TCR⁻/CD3⁻/CD7⁻ 的细胞群。3CAR 或 7CAR 细胞可特异性杀伤具有相应 CD3 和/或 CD7 表达的白血病细胞系及原代 T-ALL 细胞。体外及体内人-鼠嵌合模型中,共培养的 3CAR/7CAR 细胞对 CD3⁺CD7⁺ T-ALL 靶细胞的细胞毒性最高。尽管据报道 APOBEC 编辑器可能不依赖向导序列对 DNA 和 RNA 进行脱氨,本研究未发现影响 CAR 抗原特异性结合区域的明显脱靶活性或非特异性碱基转换,否则可能改变 T 细胞特异性。联合输注抗相互杀伤的抗 T 细胞 CAR-T,可能有助于 T 细胞恶性肿瘤患者在异基因造血干细胞移植(allo-HSCT)前实现更深的分子缓解。
Targeting T cell malignancies using chimeric antigen receptor (CAR) T cells is hindered by 'T v T' fratricide against shared antigens such as CD3 and CD7. Base editing offers the possibility of seamless disruption of gene expression of problematic antigens through creation of stop codons or elimination of splice sites.
We describe the generation of fratricide-resistant T cells by orderly removal of TCR/CD3 and CD7 ahead of lentiviral-mediated expression of CARs specific for CD3 or CD7. Molecular interrogation of base-edited cells confirmed elimination of chromosomal translocations detected in conventional Cas9 treated cells. Interestingly, 3CAR/7CAR co-culture resulted in 'self-enrichment' yielding populations 99. 6% TCR-/CD3-/CD7-. 3CAR or 7CAR cells were able to exert specific cytotoxicity against leukaemia lines with defined CD3 and/or CD7 expression as well as primary T-ALL cells.
Co-cultured 3CAR/7CAR cells exhibited highest cytotoxicity against CD3 + CD7 + T-ALL targets in vitro and an in vivo human:murine chimeric model. While APOBEC editors can reportedly exhibit guide-independent deamination of both DNA and RNA, we found no problematic 'off-target' activity or promiscuous base conversion affecting CAR antigen-specific binding regions, which may otherwise redirect T cell specificity.
Combinational infusion of fratricide-resistant anti-T CAR T cells may enable enhanced molecular remission ahead of allo-HSCT for T cell malignancies.
MEMBER ACCOUNT
登录成功会直接打开下一页。